{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004508","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.387501+00:00","generated_at":"2026-05-18T05:54:37.070101+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Harvard Bioscience appoints John Duke as CEO; Q2 revenue anticipated at $20.4M","bullets":["Jim Green resigns as President & CEO effective July 28, 2025; retirement not due to any disagreement.","John Duke (current board member) appointed CEO effective July 28; base salary $480K, 500k RSU grant.","Rob Gagnon and Seth Benson appointed to Board; Gagnon to chair Audit and Compensation committees.","Preliminary Q2 2025 revenue of $20.4 million; gross margin guidance reiterated at 55%-57%.","Full Q2 2025 financial results expected to be reported on August 11, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004508","json":"https://secwatch.observer/filing/0001171843-25-004508.json","markdown":"https://secwatch.observer/filing/0001171843-25-004508.md","text":"https://secwatch.observer/filing/0001171843-25-004508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325004508/0001171843-25-004508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325004508/f8k_071725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:54:37.070101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}